Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer

Ferroptosis Among the Antiproliferative Pathways Activated by a Lipophilic Ruthenium(III) Complex as a Candidate Drug for Triple-Negative Breast Cancer

<b>Background/Objectives</b>: In the context of preclinical studies, we have hitherto showcased that a low-molecular-weight ruthenium(III) complex we named AziRu holds significant potential for further developments as an anticancer candidate drug. When appropriately converted into stable...

Full description

Saved in:
Bibliographic Details
Main Authors: Maria Grazia Ferraro, Federica Iazzetti, Marco Bocchetti, Claudia Riccardi, Daniela Montesarchio, Rita Santamaria, Gabriella Misso, Marialuisa Piccolo, Carlo Irace
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Pharmaceutics
Subjects:
lipophilic Ru(III) complexes
antitumor Ru(III)-based drugs
triple-negative breast cancer (TNBC)
iron
oxidative stress
regulated cell death (RCD)
Online Access:https://www.mdpi.com/1999-4923/17/7/918
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items